PMID- 12614151
OWN - NLM
STAT- MEDLINE
DCOM- 20030616
LR  - 20131121
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 42
IP  - 9
DP  - 2003 Mar 11
TI  - Structures of human thymidylate kinase in complex with prodrugs: implications for
      the structure-based design of novel compounds.
PG  - 2568-77
AB  - Nucleoside analogue prodrugs are dependent on efficient intracellular stepwise
      phosphorylation to their triphosphate form to become therapeutically active. In
      many cases it is this activation pathway that largely determines the efficacy of 
      the drug. To gain further understanding of the determinants for efficient
      conversion by the enzyme thymidylate kinase (TMPK) of clinically important
      thymidine monophosphate analogues to the corresponding diphosphates, we solved
      the crystal structures of the enzyme, with either ADP or the ATP analogue AppNHp 
      at the phosphoryl donor site, in complex with TMP, AZTMP (previous work), NH2TMP,
      d4TMP, ddTMP, and FLTMP (this work) at the phosphoryl acceptor site. In
      conjunction with steady-state kinetic data, our structures shed light on the
      effect of 3'-substitutions in the nucleoside monophosphate (NMP) sugar moiety on 
      the catalytic rate. We observe a direct correlation between the rate of
      phosphorylation of an NMP and its ability to induce a closing of the enzyme's
      phosphate-binding loop (P-loop). Our results show the drastic effects that slight
      modifications of the substrates exert on the enzyme's conformation and, hence,
      activity and suggest the type of substitutions that are compatible with efficient
      phosphorylation by TMPK.
FAU - Ostermann, Nils
AU  - Ostermann N
AD  - Department of Physical Biochemistry, Max Planck Institute for Molecular
      Physiology, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany.
FAU - Segura-Pena, Dario
AU  - Segura-Pena D
FAU - Meier, Chris
AU  - Meier C
FAU - Veit, Thomas
AU  - Veit T
FAU - Monnerjahn, Christian
AU  - Monnerjahn C
FAU - Konrad, Manfred
AU  - Konrad M
FAU - Lavie, Arnon
AU  - Lavie A
LA  - eng
SI  - PDB/1NMX
SI  - PDB/1NMY
SI  - PDB/1NMZ
SI  - PDB/1NN0
SI  - PDB/1NN1
SI  - PDB/1NN3
SI  - PDB/1NN5
GR  - R01-AI46943/AI/NIAID NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (2',3'-dideoxy-2',3'-didehydrothymidine monophosphate)
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Cyclosaligenyl-2',3'-didehydro-2',3'-dideoxythymidine monophosphate)
RN  - 0 (Dideoxynucleotides)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Prodrugs)
RN  - 0 (Thymine Nucleotides)
RN  - 365-07-1 (Thymidine Monophosphate)
RN  - 42214-32-4 (3'-amino-3'-deoxythymidine 5'-monophosphate)
RN  - BO9LE4QFZF (Stavudine)
RN  - EC 2.7.4.4 (Nucleoside-Phosphate Kinase)
RN  - EC 2.7.4.9 (dTMP kinase)
RN  - VC2W18DGKR (Thymidine)
SB  - IM
MH  - Anti-HIV Agents/chemical synthesis/chemistry
MH  - Crystallography, X-Ray
MH  - Dideoxynucleotides
MH  - *Drug Design
MH  - Humans
MH  - Kinetics
MH  - Macromolecular Substances
MH  - Nucleoside-Phosphate Kinase/*chemistry
MH  - Prodrugs/chemical synthesis/*chemistry
MH  - Protein Conformation
MH  - Stavudine/*analogs & derivatives/chemistry
MH  - Structure-Activity Relationship
MH  - Substrate Specificity
MH  - Thymidine/*analogs & derivatives/chemistry
MH  - Thymidine Monophosphate/*analogs & derivatives/chemistry
MH  - Thymine Nucleotides
EDAT- 2003/03/05 04:00
MHDA- 2003/06/17 05:00
CRDT- 2003/03/05 04:00
PHST- 2003/03/05 04:00 [pubmed]
PHST- 2003/06/17 05:00 [medline]
PHST- 2003/03/05 04:00 [entrez]
AID - 10.1021/bi027302t [doi]
PST - ppublish
SO  - Biochemistry. 2003 Mar 11;42(9):2568-77. doi: 10.1021/bi027302t.